Talazoparib was evaluated in phase I trials in patients with one of the following cancers: triple-negative breast cancer, ovarian cancer, prostate cancer, pancreatic cancer, and identified germline mutations of BRCA1 and BRCA2. This evidence concerns the gene BRCA1 and Familial prostate cancer.